Study identifies 2 new genes responsible for Alzheimer’s disease among African-Americans

The findings, which appear online in the journal Alzheimer’s and Dementia, may lead to the development of new therapies specifically targeting those genes.

“There are currently no medications for AD that slow or stop the progression of the disease. Genes that increase risk for AD are potential targets for new disease-modifying AD drug therapies. Our study identifies two potentially “drugable” targets,” explains corresponding author Jesse Mez, MD, MS, assistant professor of neurology at BUSM and associate director of the Boston University Alzheimer’s Disease & CTE Center Clinical Core.

Click here to for full transcript